Hong Kong Stock Movement: PEGBIO CO-B surged 23.15%, with clear capital flow; what is stirring the market sentiment?

Hong Kong Stock Movement PEGBIO CO-B surged 23.15%, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Kangfang Biotech fell 5.99%, with a trading volume of HKD 996 million, and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Innovent Biologics fell 1.83%. Based on recent key news: On May 15, Innovent Biologics signed a strategic cooperation agreement with Tianjin Medical University, focusing on scientific research innovation and achievement transformation in major disease fields. This move may enhance the company's competitiveness in related fields, but it has not boosted the stock price in the short term. On May 15, the National Healthcare Security Administration announced comprehensive regulation of the pharmaceutical retail industry, which may affect Innovent Biologics' market sales strategy, leading to pressure on the stock price. The pharmaceutical industry is facing regulatory pressure, and capital outflow is evident. Kelun-Biotech fell 2.89%, with a trading volume of HKD 440 million, and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Market Capitalization in the Industry BeiGene fell 2.45%. Based on recent news, On May 18, BeiGene provided a new growth curve for Tislelizumab and other early pipelines in the solid tumor field. Although the hematology business can contribute stable cash flow, the competition in the solid tumor track is fierce, affecting the stock price decline. Source: Radar Finance On May 15, Innovent Biologics plans to accelerate the layout of new technology platforms such as ADC and molecular glue, promoting high-quality development of innovative drugs and medical devices, with industry policy dividends affecting BeiGene's stock price. Source: Radar Finance On May 15, Heng Rui Medicine mentioned in its annual report that the sales revenue of innovative drugs continues to grow, while the proportion of generic drug revenue decreases, with intensified industry competition affecting BeiGene's stock price. Source: Radar Finance. The competition in the innovative drug industry is intensifying, and policy dividends are emerging